Table 1 |
|
|
Patients characteristics and tumour parameters |
|
|
Variable (N = 467) |
Data |
|
|
|
|
Age at Diagnosis, years |
|
|
Mean and standard deviation |
59 ± 13 |
|
Range |
64 (Min 28; Max 92) |
|
Tumour Size (cm) |
|
|
Mean and standard deviation |
3.110 cm ± 2.00 cm |
|
Range |
15.6 (Min 0.4; max 16) |
|
T1: < 2 cm |
101 (24.7%) |
|
T2: 2-5 cm |
245 (59.9%) |
|
T3: > 5 cm |
63 (15.4%) |
|
Not assessed |
58 |
|
Lymph Node Invasion |
|
|
Present |
207 (56.6%) |
|
Absent |
159 (43.4%) |
|
Not assessed |
101 |
|
Histological Grade |
|
|
Grade I |
81 (18.3%) |
|
Grade II |
135 (30.5%) |
|
Grade III |
227 (51.2%) |
|
Not assessed |
24 |
|
Oestrogen receptor |
|
|
Positive |
309 (66.5%) |
|
Negative |
156 (33.5%) |
|
Not assessed |
2 |
|
Progesterone Receptor |
|
|
Positive |
228 (48.9%) |
|
Negative |
238 (51.1%) |
|
Not assessed |
1 |
|
HER2 |
|
|
Positive |
68 (14.7%) |
|
Negative |
395 (85.3%) |
|
Not assessed |
4 |
|
Nottingham Prognostic Index |
|
|
NPI < 3.4 |
99 (24.4%) |
|
3.4 ≤ NPI ≤ 5.4 |
188 (46.4%) |
|
NPI > 5.4 |
118 (29.2%) |
|
Not assessed |
62 |
|
Molecular Subtype |
|
|
Luminal |
343 (73.6%) |
|
HER2 Over-expressing |
33 (7.1%) |
|
Triple Negative |
90 (19.3%) |
|
|
|
|
Albergaria et al. BMC Cancer 2011 11:299 doi:10.1186/1471-2407-11-299 |
|
